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Abstract
The members of lethal-7 (Let-7) microRNA (miRNA) family are involved in
regulation of cell differentiation and reprogramming of somatic cells into
induced pluripotent stem cells. However, their function in the heart is not
known. In this study, we examined the effect of inhibiting the function of Let-
7c miRNA on the progression of postinfarction left ventricular (LV) remodeling
in mice. Myocardial infarction was induced with permanent ligation of left
anterior descending coronary artery with a 4-week follow-up period. Let-7c
miRNA was inhibited with a specific antagomir administered intravenously.
The inhibition of Let-7c miRNA downregulated the levels of mature Let-7c
miRNA and its other closely related members of Let-7 family in the heart and
resulted in increased expression of pluripotency-associated genes Oct4 and Sox2
in cardiac fibroblasts in vitro and in adult mouse heart in vivo. Importantly,
Let-7c inhibitor prevented the deterioration of cardiac function postinfarction,
as demonstrated by preserved LV ejection fraction and elevated cardiac output.
Improvement in cardiac function by Let-7c inhibitor postinfarction was associ-
ated with decreased apoptosis, reduced fibrosis, and reduction in the number of
discoidin domain receptor 2–positive fibroblasts, while the number of c-kit+
cardiac stem cells and Ki-67+ proliferating cells remained unaltered. In conclu-
sion, inhibition of Let-7 miRNA may be beneficial for the prevention of postin-
farction LV remodeling and progression of heart failure.
Abbreviations
LSD, least significant difference; ANOVA, analysis of variance; TUNEL, transferase-
mediated dUTP nick end labeling; MAPK, mitogen-activated protein kinase; ERK,
extracellular signal-regulated kinase; SDS-PAGE, sodium dodecyl sulfate polyacryl-
amide gel electrophoresis; FBS, fetal bovine serum; LVID, LV internal dimensions;
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Introduction
Heart failure is one of the most common causes of car-
diovascular morbidity and mortality, and its prevalence is
rapidly increasing as the mean age of the population
advances (McMurray et al. 2012). As a result, novel thera-
peutic strategies are necessary. The key pathophysiological
process that ultimately leads to heart failure is left ven-
tricular (LV) remodeling (Sutton and Sharpe 2000; Shah
and Mann 2011), caused by disorders that chronically
increase workload, such as myocardial infarction (MI)
or pressure overload due to hypertension (Jessup and
Brozena 2003; McMurray and Pfeffer 2005). Myocardial
remodeling is a complex process characterized by struc-
tural, functional, electrophysiological, cellular, and molec-
ular events (Shah and Mann 2011; Burchfield et al. 2013).
At the cellular level, myocyte loss, hypertrophy, fibrosis,
inflammation, and the limited endogenous regenerative
capacity of cardiac myocytes contribute to the adverse
myocardial remodeling (Burchfield et al. 2013). Because
these events are highly interrelated and multilayered
molecular pathways are involved in LV remodeling (Lips
et al. 2003; Heineke and Molkentin 2006), targeting a sin-
gle molecule or process may not be sufficient to prevent
progression into heart failure.
MicroRNAs (miRNAs) are small single-stranded, non-
coding RNAs that bind to target mRNA and inhibit
translation or promote degradation of the transcript,
thereby suppressing protein expression (Bartel 2004). Any
given miRNA has the potential to target multiple mRNAs.
The involvement of miRNAs in various physiological and
pathophysiological processes in the cardiovascular system
includes cardiac development, heart failure, atherosclero-
sis, and arrhythmias (Quiat and Olson 2013; Condorelli
et al. 2014; Santulli et al. 2014). Several miRNAs have
been linked to myocyte hypertrophy, apoptosis, fibrosis,
stem cell function, and regeneration (van Rooij and Olson
2012; Seeger et al. 2013), prompting the possibility for
miRNAs as novel therapeutic targets for LV remodeling.
One attractive candidate for this purpose is lethal-7 (Let-
7), which was initially discovered as an essential develop-
mental gene in Caenorhabditis elegans and later, as one of
the first miRNAs (Pasquinelli et al. 2000; Reinhart et al.
2000). In embryonic stem (ES) cells, miRNAs of Let-7
family play essential role as suppressors of stem cell pluri-
potency and somatic cell reprogramming (Roush and
Slack 2008; Peter 2009). Let-7 miRNAs are also expressed
in the heart (Chen et al. 2007; Landgraf et al. 2007), but
their role in myocardial remodeling and heart failure is
unknown.
In this study, we provide the first evidence for the ben-
eficial effect of inhibition of Let-7 miRNA on cardiac
function. The inhibition of Let-7 increased expression of
pluripotency genes Sox2 and Oct4 in cardiac fibroblasts
in vitro and in the adult mouse heart in vivo. In experi-
mental MI model, inhibition of Let-7 miRNA postinfarc-
tion maintained LV systolic function in vivo. This
improvement of cardiac function was associated with
attenuation of fibrosis and apoptosis, and alterations in
fibroblast subpopulations. Together, these data suggest
that inhibition of Let-7 miRNA is a promising therapy
for postinfarction LV remodeling.
Materials and Methods
Animals
All experimental protocols were approved by the Animal
Use and Care Committee of the University of Oulu and
the Provincial Government of Western Finland Depart-
ment of Social Affairs and Health (ESAVI-2010-03931/
Ym-23). The investigations conform to the Guiding
Principles for Research Involving Animals. The results
were reported in accordance with the ARRIVE guide-
lines for reporting experiments involving animals
(Kilkenny et al. 2010; McGrath et al. 2010). Total num-
ber of 492 male C57BL/6JOlaHsd mice (Harlan, Horst,
the Netherlands) were used for this study. The mice
were maintained in plastic cages at a constant 21°C
temperature with a 12 h light–dark cycle and had free
access to food (Teklad Global Rodent diet, Harlan,
Indianapolis, IN) and water.
MI in mice
MI model developed by Gao et al. (2010) was used.
Mice were anesthetized with 2% isoflurane inhalation
and pericardial incision was performed under thoracot-
omy. Left anterior descending (LAD) coronary artery
was permanently ligated. Carprofen (5 mg/kg, Rimadyl)
and buprenorphine (0.05–0.1 mg/kg, Vetergesic) were
administered as perioperative analgesia and mice were
hydrated with 0.5-mL glucose (50 mg/mL) solution sub-
cutaneously. Postoperative analgesia (carprofen once per
day, buprenorphine twice per day) was administered for
3 days.
Inhibition of Let-7c
To study the effects of Let-7c inhibition on cardiac func-
tion and myocardial structure, the single-stranded custom
Let-7c antagomir was synthesized using locked-nucleic-
acid-modified (LNA) technology (Exiqon, Vedbaek,
Denmark). The sequence (UGAGGUAGUAGGUUGUAU
GGUU) was obtained from miRBase (http://www.
mirbase.org/). Lyophilized Let-7c inhibitor (sequence
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50-ACCATACAACCTACT) was resuspended into phos-
phate-buffered saline (PBS) as 10 mg/mL and stored
at 20°C until use. A custom scramble-sequence LNA
inhibitor provided by Exiqon (sequence 50-
ACGTCTATACGCCCA) was used as a negative control.
Immediately after LAD ligation, Let-7c inhibitor was
administered intravenously via tail vein at the dose of
20 mg/kg according to earlier studies demonstrating that
single intravenous doses of antagomirs ranging between 3
and 80 mg/kg in vivo cause permanent downregulation of
miRNAs in target tissue for several weeks (Frost and van
Rooij 2010; Montgomery and van Rooij 2011).
Echocardiography
Cardiac function was analyzed by transthoracic echocardi-
ography using Vevo 2100 high-frequency, high-resolution
ultrasound system with 40 MHz linear transducer (MS-
550S; Visual Sonics, Toronto, Ontario, Canada) as
described (Kerkel€a et al. 2013). Mice were sedated with
isoflurane inhalation anesthesia. LV morphology and sys-
tolic function were evaluated by two-dimensional M-
mode recording. To analyze diastolic function, transmitral
flow velocity was measured through pulsed-wave Doppler
targeted by apical four-chamber view.
Stroke volume was evaluated from echocardiographic
data by calculating the difference between LV volume in
diastole and systole, determined from LV internal dimen-
sions (LVID), respectively. The formula is the following:
stroke volume = LV end diastolic volume ((7/
(2,4 + LVID;d) 9 LVID;d3)) – LV end systolic volume
((7/(2,4 + LVID;s) 9 LVID;s3)).
Cell culture
Adult cardiac fibroblasts were isolated from 8-week-old
C57BL6 mice as previously described (Kerkel€a et al.
2013). Briefly, mouse was anesthetized with isoflurane,
heart was excised rapidly and cannulated through the
aorta. Fibroblasts were isolated after retrograde perfusion
with HEPES-buffered Tyrode’s solution supplemented
with 0.1% collagenase type II (Worthington, Lakewood,
NJ) and 2,3-butandione-monoxime. Fibroblasts were
resuspended into DMEM/F12 (Sigma, St. Louis, MO)
supplemented with 10% fetal bovine serum (FBS) (Invi-
trogen, Life Technologies, Carlsbad, CA), 2 mmol/L
L-glutamine and penicillin–streptomycin (Sigma). The
medium was changed the following day and every 2 days
thereafter. Let-7c inhibitor (100 nmol/L) or equal concen-
tration/volume of control (PBS or scramble) was applied
into the culture the following day after isolation. After
7 days of treatment, cells were washed once with PBS and
frozen at 70°C.
RNA isolation and quantitative real-time PCR
Mice were euthanized with CO2 and sacrificed by decapi-
tation. Heart, kidney, and liver were excised, frozen in
liquid nitrogen, and stored at 70°C. RNA was isolated
with Trizol (Invitrogen). To analyze the levels of Let-7
expression, cDNA was synthesized from 0.1 lg of total
RNA with miScript RT kit (Qiagen, Hilden, Germany).
miRNA levels were measured by real-time quantitative
(qPCR) analysis with Let-7 (for the sequences, see Table
S1) and reference gene RNU6B miScript primer assays
and miScript SYBR green PCR kit (Qiagen). To analyze
other genes (for the sequences, see Table S2), cDNA was
synthesized from 1 lg of RNA with Transcriptor First
Strand cDNA synthesis kit (Roche Applied Science, Penz-
berg, Germany). The expression levels were evaluated on
an ABI Prism 7700 Sequence Detection System (Applied
Biosystems, Life Technologies, Carlsbad, CA) as previ-
ously described (Tenhunen et al. 2006).
Western blotting
To extract the cytoplasmic proteins, the LV free wall tis-
sue was broken and reduced to a powder in liquid nitro-
gen (Tenhunen et al. 2006). The thawed LV powder or
cardiac fibroblasts were lysed with 20 mmol/L Tris-HCl,
150 mmol/L NaCl, 1 mmol/L ethylenediaminetetraacetic
acid, 1 mmol/L ethyleneglycoltetraacetic acid, 1% Triton-
X100, 2.5 mmol/L sodium pyrophosphate, 1 mmo/L b-
glycerophosphate, and 1 mmol/L dithiothreitol (pH 7.5)
supplemented with protease and phosphatase inhibitor
cocktails (Sigma). The lysate was centrifuged at
12,500 rpm for 20 min at 4°C and the supernatant was
transferred to a new tube as the total protein extract. The
protein concentrations were determined with colorimetric
protein assay (Bio-Rad Laboratories, Hercules, CA). Pro-
tein samples (40 lg) were denatured at 97°C for 5 min
and loaded on sodium dodecyl sulfate polyacrylamide gel
electrophoresis (SDS-PAGE), run with 200 V and trans-
ferred to 0.45 lm Optitran BA-S 85 nitrocellulose mem-
brane (Whatman, GE Healthcare Life Sciences, Uppsala,
Sweden) with 100 V for 2 h. The membranes were incu-
bated for 1 h at RT in blocking buffer (Odyssey, LI-COR,
Lincoln, NE) diluted into tris-buffered saline (TBS)
(50 mmol/L Tris, 200 mmol/L NaCl, pH 7.4). Mem-
branes were then incubated overnight with primary anti-
body Sox2 (0.5 lg/mL; Pierce Antibodies, Thermo
Scientific, Rockford, IL); extracellular signal-regulated
kinase (ERK) or p38 mitogen-activated protein kinase
(MAPK) (0.1 lg/mL Cell Signaling, Danvers, MA); or
GAPDH (0.01 lg/mL, Millipore, Billerica, MA) in block-
ing buffer, washed with TBS-0.05% Tween-20 and incu-
bated with secondary antibody (goat-anti-rabbit Alexa
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Fluor 680; Molecular Probes, Life Technologies, Carlsbad,
CA; goat-anti-mouse IRDye 800; Rockland Immunochem-
icals, Gilbertsville, PA) 1 h at RT. Antibody binding was
detected by Odyssey Infrared Imaging System (LI-COR)
and quantified using the public domain NIH Image pro-
gram (developed at the U.S. National Institutes of Health,
Bethesda, MD).
Histology and image analysis
Tissue sections from LV were fixed in phosphate-buf-
fered 10% formaline (pH 7.0) and embedded in paraffin
(Serpi et al. 2011). Five-lm thick transversal sections
were cut at the level of the papillary muscles. Sections
were stained with Masson’s trichrome to evaluate the
fibrosis and cardiomyocyte cross-sectional area. Fibrosis
and cardiomyocyte area were measured by the Nikon
(Melville, NY) NIS-Elements BR 2.30 program from five
representative high-power fields from the infarcted myo-
cardium. Infarction scar was measured as a percentage
from the LV circumference. Cardiomyocytes were also
stained with 5 lg/mL of wheat germ agglutinin Alexa
Fluor 488-conjugate (Molecular Probes), as described
(Condorelli et al. 2002; Santulli et al. 2012). The Apop-
Tag in situ apoptosis detection kit (S7100; Chemicon,
Millipore, Billerica, MA) for 30-end labeling of apoptotic
DNA by terminal deoxynucleotidyl transferase-mediated
dUTP nick end labeling (TUNEL) method was used to
analyze apoptosis (Rys€a et al. 2010). Primary antibody
for c-kit (sc-168; Santa Cruz Biotechnology, Dallas, TX)
and Ki-67 (M7248; Dako, Glostrup, Denmark) with
EnVision Detection System (Dako) for secondary detec-
tion was used to determine the number of cardiac stem
cells and cell proliferation, respectively. Fibroblasts were
double stained by primary antibodies for discoidin
domain receptor 2 (DDR2, sc-8989; Santa Cruz Biotech-
nology) and octamer-binding transcription factor 4
(Oct4, sc-5279; Santa Cruz Biotechnology). Number of
Oct4+/DDR2+ double-positive cells were analyzed by
immunofluorescence microscopy. CY2-conjugated anti-
mouse IgG (800-656-7625; Rockland) and Alexa Fluor
568 goat anti-rabbit IgG (A11036; Invitrogen) were used
for secondary detection. Fibroblast activation protein
(FAP, ab28244; Abcam, Cambridge, UK) was used to
further evaluate fibroblast subpopulations. Antibody for
CD31 (sc-1506R; Santa Cruz Biotechnology) was used to
stain endothelial cells in the LV. The number and cross-
sectional area of capillaries was calculated from three
representative high-power fields (409 objective) with
NIS-Elements BR 2.30 program from each section choos-
ing corresponding fields from epicardial and endocardial
side of the LV at the level of the papillary muscles as
described (Rys€a et al. 2010).
Statistical analysis
Results are expressed as the mean  SEM. Mann–Whitney
U test or Student’s t-test was used for comparisons
between two groups. Statistical significance between mul-
tiple groups was evaluated by one-way analysis of vari-
ance (ANOVA) followed by a least significant difference
(LSD) post hoc test. For histological data, nonparametric
Mann–Whitney U test was used. P < 0.05 was considered
statistically significant.
Results
Cardiac function, fibrosis, and LV Let-7c
mRNA expression postinfarction
To study the effects of Let-7c inhibitor on infarcted myo-
cardium, we first analyzed the effects of MI on cardiac
function and LV fibrosis in mice. Cardiac function was
analyzed 7 days after LAD ligation by transthoracic echo-
cardiography. A significant decrease in LV ejection frac-
tion (P < 0.001, Fig. 1A) and fractional shortening
(P < 0.001, Fig. 1B; for other echocardiography parame-
ters, see Table S3) was observed. When compared to
sham-operated mice, MI resulted in 3.6-fold increase in
the fibrotic area in the LV (P < 0.01, Fig. 1C).
We next evaluated the alterations in the fibroblast sub-
populations postinfarction. Fibroblasts can be divided
into subpopulations based on the morphology and
expression of cell surface markers (Zeisberg and Kalluri
2010). Of these markers, DDR2 has been used to identify
cardiac fibroblasts (Goldsmith et al. 2004; Camelliti et al.
2005). LV fibrosis was accompanied by increase in the
number of DDR2+ cells as observed 3 and 5 days after
MI (Fig. 1D). Because DDR2 is not specific to cardiac
fibroblasts but is also expressed in cells of lymphocytic
lineages (Zeisberg and Kalluri 2010), FAP was used to
further evaluate fibroblast subpopulations. Also the
amount of FAP+ cells increased both at 3 and 5 days after
MI (Fig. 1E). The absolute number of FAP+ cells was
lower than that of DDR2+ cells at day 3 postinfarction
(Fig. 1D and E) suggesting a more important role for
DDR2+ fibroblast population in the progression of cardiac
fibrosis. Furthermore, an increase in the mRNA levels of
DDR2 was observed (Fig. 1F). Interestingly, levels of Let-
7c miRNA were 70% lower 5 days after MI (P < 0.05,
Fig. 1G).
Efficacy of Let-7c miRNA inhibitor
To evaluate the effects of Let-7c inhibition on myocardial
remodeling, we injected Let-7c inhibitor, control nonsense
sequence (scramble), or PBS intravenously via tail vein.
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When compared to PBS control group 4 weeks after
injections and LAD ligation, a 50% decrease in LV levels
of Let-7c miRNA was noted (P < 0.05, Fig. 2A). This
decrease was 63% in comparison to scramble group
(P < 0.001, Fig. 2B). We also injected Let-7c inhibitor
into normal mice without MI and observed a 42%
decrease in LV Let-7c miRNA levels after 2 weeks
(P = 0.12, Fig. 2C). Moreover, Let-7c inhibitor resulted
in a 98% decrease in the levels of Let-7c miRNA both in
the liver and kidney (P < 0.05, Fig. 2D), organs responsi-
ble for the elimination of antagomirs.
The sequences of other members of Let-7 family closely
resemble to that of Let-7c (Table S1) differing one to
few nucleotides from Let-7c sequence. Therefore, we
(A) (B) (C)
(D) (E)
(F) (G)
Figure 1. Effects of myocardial infarction (MI) induced by ligation of left anterior descending (LAD) artery in mice. (A) Left ventricular (LV)
ejection fraction and (B) fractional shortening decreased significantly postinfarction. (C) MI increased the fibrotic area in the LV. (D) Number of
DDR2+ and (E) FAP+ cells were significantly elevated at 3 and 5 days postinfarction. (F) MI resulted an increase in DDR2 mRNA levels at 4 weeks
postinfarction. (G) Let-7c miRNA levels were significantly decreased in LV 5 days after MI. Results are mean  SEM. (A–C) n = 8–11, (D, E, G)
n = 3–6, (F) n = 6–9. White column: sham-operated; black column: MI. Data were analyzed with Student’s t-test. *P < 0.05, **P < 0.01, and
***P < 0.001 versus sham. DDR2, discoidin domain receptor 2; FAP, fibroblast activation protein; Let-7c, lethal-7c.
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(A) (B) (C)
(E)
(G) (H) (I)
(F)
(D)
Figure 2. Efficacy of Let-7c inhibitor in vivo and in vitro. Let-7c inhibitor decreased significantly the levels of Let-7c miRNA in the infarcted
myocardium compared to PBS-treated (A) or scramble-treated (B) mice 4 weeks after i.v. injection. (C) There was also a tendency for Let-7c
miRNA to decrease in normal mice 2 weeks after administration of Let-7c inhibitor. (D) Let-7c inhibition reduced Let-7c miRNA levels in the
kidney and liver in mice 4 weeks postinfarction. (E) Let-7c inhibitor decreased the expression of closely related members of Let-7 family. (F) Let-7c
is expressed in cardiomyocytes and fibroblasts to the similar extent as analyzed from adult mouse heart immediately after ex vivo fractionation of
cell types. Inhibition of Let-7c increased Sox2 (G) protein and (H) mRNA levels in isolated cardiac mouse fibroblasts in vitro. (I) Let-7c inhibitor
resulted in elevation of LV Oct4 and Sox2 mRNA levels in normal mice 2 weeks after administration of Let-7c inhibitor. Results are mean  SEM.
(A, B, E) n = 7–8, (C, F, I) n = 4–5, (D) n = 4–6, (G) n = 3, (H) n = 8–9. White column: control; black column: Let-7c inhibitor. Data were
analyzed with Student’s t-test. *P < 0.05 and ***P < 0.001 versus control. Let-7c, lethal-7c; miRNA, microRNA; PBS, phosphate-buffered saline;
LV, left ventricular; Oct4, octamer-binding transcription factor 4.
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performed qPCR to analyze the effect of Let-7c inhibitor
treatment on other members of the Let-7 family. As
shown in Figure 2E, Let-7c antagomir also significantly
decreased miRNA levels of other closely related members
of Let-7c family, namely -7b, -7d, and -7f. Overall, the
expression of the members of Let-7 family whose
sequences differ from Let-7c more prominently, that is,
-7g and -7i were not reduced by Let-7c inhibitor and the
expression of -7i even increased with the treatment of
Let-7c inhibitor (Fig. 2E), probably due to compensatory
mechanism(s). Despite the fact that Let-7c inhibitor
affected other members of the Let-7 family, the highest
reduction was seen in Let-7c miRNA levels over other
miRNAs of Let-7 family both in heart (Fig. 2E) and in
liver (data not shown). To study the Let-7c expression in
cardiac cell types, we fractionated cardiomyocytes and
fibroblasts from adult mouse hearts as described previ-
ously (Kerkel€a et al. 2013). As shown in Figure 2F, the
Let-7c miRNA expression was similar in cardiomyocytes
and fibroblasts when analyzed from fractionated cells.
When the effects of loss of Let-7c function were ana-
lyzed in cell culture using cardiac fibroblasts, an activa-
tion of induced pluripotent stem (iPS) cell–related genes
was observed. Sox2 protein levels were elevated in
response to Let-7c miRNA inhibition (P < 0.05, Fig. 2G),
and also mRNA levels of Oct4 (6.6-fold) and Sox2 (10.9-
fold) increased in fibroblasts (P < 0.05, Fig. 2H). Compa-
rable changes were observed in normal adult mouse heart
in vivo: mRNA levels of Oct4 (5.0-fold) and Sox (1.8-
fold) increased 2 weeks after Let-7c inhibitor injection
(Fig. 2I). On the other hand, the levels of cMyc and
Kruppel-like factor 4 (Klf4) mRNA remained unaltered
by Let-7c inhibition (Fig. 2I). To further characterize the
selectivity of Let-7c inhibitor in vivo, we studied the
expression of miRNA-125b, a negative regulator of the
p53 tumor suppressor pathway (Le et al. 2009), and
miRNA-126, a regulator of angiogenesis (Liu et al. 2009),
and did not detect any changes in their expression in the
heart, liver, or kidney (data not shown).
Inhibition of Let-7c improves cardiac
function after MI
Cardiac function was evaluated by echocardiography
3 days and 4 weeks after MI. Interestingly, inhibition of
Let-7c miRNA prevented the decrease in LV ejection frac-
tion postinfarction (Fig. 3A and B). When the change in
LV ejection fraction in scramble and Let-7c inhibitor
groups was analyzed, a statistically significant difference
was noted (P < 0.05, Fig. 3C). Accordingly, Let-7c inhibi-
tor increased stroke volume by 30% (P = 0.08, Fig. 3D)
and cardiac output by 20% (P < 0.05, Fig. 3E) at 4 weeks
after MI. Let-7c inhibitor did not affect LV posterior wall
thickness (Fig. 3F and G). Also, no alterations in diastolic
function in response to inhibition of Let-7c were observed
(Table S4).
Let-7c inhibition reduces cardiac fibrosis
postinfarction
Inhibition of Let-7c miRNA decreased the level of fibrosis
in the LV after MI. Percentage of fibrotic area in the
noninfarcted myocardium was 64% lower in Let-7c inhib-
itor-treated mice (P < 0.05, Fig. 4A). There was also a
tendency for a smaller infarction scar size, as measured
from the LV circumference (Fig. 4B). Interestingly, the
reduction in fibrosis triggered by Let-7c inhibitor was
accompanied by a lower number of DDR2+ cells as ana-
lyzed by immunofluorescence microscopy (Fig. 4C).
There was also a tendency for the number of Oct+ and
Oct+/DDR2+ double-positive cells to increase (Fig. 4C
and D), however, these changes were not statistically sig-
nificant. On the other hand, Let-7c inhibitor did not sig-
nificantly alter LV expression of genes involved in the
induction of iPS cells (Fig. 5A) or fibrosis (Fig. 5B) mea-
sured from the MI border zone. Moreover, the LV levels
of p38, ERK, and phospho-ERK proteins remained
unchanged by Let-7c inhibition (data not shown).
Apoptosis, angiogenesis, cell proliferation,
and c-kit+ cardiac stem cells
In addition to fibrosis, apoptotic cell death, angiogenesis,
cell proliferation, and cardiac stem cell recruitment play
key roles in the regulation of myocardial remodeling
(Quintavalle et al. 2011; Santulli et al. 2012; Burchfield
et al. 2013). Therefore, we performed immunohistochem-
ical staining procedures to evaluate morphological
changes in the heart in response to administration of Let-
7c inhibitor with MI. A significantly reduced number of
TUNEL+ apoptotic cells in the border zone of infarction
was observed by Let-7c inhibition (P < 0.05, Fig. 6A).
Double immunofluorescence staining of TUNEL+ cells
with cardiomyocyte marker a-actinin or fibroblast marker
DDR2 showed that the apoptotic cells were mainly fibro-
blasts (Fig. 6B). Instead, myocyte cross-sectional area
(Fig. 6C), the number of c-kit+ cardiac stem cells
(Fig. 6D) and Ki-67+ proliferating cells (Fig. 6E)
remained unaltered in the border zone by Let-7c inhibitor
postinfarction. In addition, Let-7c inhibitor did not affect
capillary density or area as assessed from LV (Fig. 6F).
Discussion and Conclusions
Despite substantial efforts in the recent years, the
detrimental postinfarction remodeling with concomitant
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fibrosis, hypertrophy, cell death, and limited regenerative
capacity remains an unsolved challenge (Burchfield et al.
2013). The finding that functions of miRNAs are intensi-
fied under pathophysiological conditions and that
miRNAs influence the progression of LV remodeling has
opened new therapeutic possibilities (van Rooij and
Olson 2012; Kumarswamy and Thum 2013; Seeger et al.
2013). Depending on the abundance of a miRNA and its
targets, as well as the physiological state of a cell, a
miRNA can act as a fine-tuner of gene expression or as
an on/off switch (van Rooij and Olson 2012). MiRNAs
are known to regulate cardiac hypertrophy, apoptosis,
endothelial cell function, and vessel growth as well as
fibrosis (Kumarswamy and Thum 2013; Quiat and Olson
2013; Seeger et al. 2013; Condorelli et al. 2014; Santulli
et al. 2014). In this study, we observed preserved systolic
function with reduction in fibrosis and apoptosis postin-
farction in mice in response to Let-7c inhibitor suggesting
that inhibition of Let-7 miRNA may be a novel therapeu-
tic tool for LV remodeling.
MiRNAs are involved in diverse biological functions,
including development, life span, cell proliferation, differ-
entiation, signaling pathways, apoptosis, and metabolism
(Sun and Lai 2013). The first two known miRNAs, Lin-4
and Let-7, were discovered in the nematode C. elegans
and controlling the timing of stem-cell division and dif-
ferentiation (Pasquinelli et al. 2000; Reinhart et al. 2000).
Let-7 and its family members are highly conserved across
(A) (B) (C)
(D) (E)
(F) (G)
Figure 3. Let-7c inhibition prevented the deterioration of systolic function after MI. (A) Representative images from echocardiography M-mode
view. (B, C) Let-7c inhibitor maintained LV ejection fraction postinfarction. (D) There was a tendency for stroke volume to increase in response to
Let-7c inhibitor. (E) Let-7c inhibitor enhanced cardiac output 4 weeks after MI. (F, G) Let-7c inhibitor had no effect on the LV posterior wall
thickness in systole (LVPW;s) or diastole (LVPW;d). Results are mean  SEM. (B–G) n = 7–8. Data were analyzed with ANOVA. *P < 0.05 versus
scramble. Let-7c, lethal-7c; MI, myocardial infarction; LV, left ventricular.
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species in sequence and function, and play a significant
role in the regulation of cell reprogramming (Roush and
Slack 2008; Peter 2009). In ES cell differentiation, Let-7
miRNA family members are augmented to suppress
pluripotency factors (Melton et al. 2010). In this study,
we targeted a Let-7 family member, Let-7c, with a miRNA
inhibitor. The Let-7c inhibitor was designed based on the
mature sequence of mouse Let-7c. With this approach,
the expression of Let-7c miRNA in the target tissue (the
heart) as well as in the tissues responsible for elimination
of antagomirs (liver and kidney) was downregulated. The
inhibition of Let-7c was functional, as reflected by
increased expression of specific pluripotency genes (Oct4,
Sox2) in cardiac fibroblasts in vitro and in the adult mice
heart in vivo. However, although Let-7c inhibitor had the
highest influence on the expression of Let-7c, also
other closely related members of the Let-7 family were
(A)
(B)
(C) (D)
Figure 4. Let-7c inhibition reduced fibrosis in the LV. (A) Let-7c
inhibitor significantly decreased the fibrotic area in the LV 4 weeks
after MI and (B) also a nonsignificant reduction in the size of
infarction scar was observed. (C) The number of DDR2+ cells
decreased in response to Let-7c inhibition, and there was a trend for
the number of Oct+ and Oct+DDR2+ cells to increase postinfarction.
(D) A representative image of Oct+DDR2+ cells. Results are
mean  SEM. (A–C) n = 5–8. White column: scramble; black column:
Let-7c inhibitor. Scale bar, 50 lm (A), 1 mm (B), 10 lm (D). Data
were analyzed with Mann–Whitney U test. *P < 0.05 versus scramble.
Let-7c, lethal-7c; LV, left ventricular; MI, myocardial infarction; DDR2,
discoidin domain receptor 2; Oct4, octamer-binding transcription
factor 4.
(A)
(B)
Figure 5. Effects of Let-7c inhibition on LV gene expression after MI.
(A) There were no significant changes in pluripotency-associated
genes with Let-7c inhibitor treatment when analyzed 4 weeks
postinfarction. (B) The activation of genes involved in the regulation
of fibrosis remained unaltered in response to Let-7c inhibition. Results
are mean  SEM (n = 7–8/group). White column: scramble; black
column: Let-7c inhibitor. Data were analyzed with Student’s t-test.
Let-7c, lethal-7c; LV, left ventricular; MI, myocardial infarction.
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(A) (B)
(C)
(E) (F)
(D)
Figure 6. Morphological changes in the LV analyzed by immunohistochemistry. (A) The number of TUNEL+ apoptotic cells decreased statistically
significantly in response to Let-7c inhibition 4 weeks after MI. (B) Apoptotic cells were noncardiomyocytes and DDR2+ fibroblasts. (C) Let-7c
inhibitor did not affect cardiomyocyte hypertrophy as assessed with cardiomyocyte cross-sectional area after Masson’s trichrome stain and when
observed with wheat germ agglutinin stain. The number of c-kit+ stem cells (D) and Ki-67+ proliferative cells (E) remained unaltered. (F) Let-7c
inhibitor had no effect on angiogenesis. Results are mean  SEM. (A–F), n = 6–8/group. White column: scramble; black column: Let-7c inhibitor.
Scale bar, 20 lm (A, C–F) and 10 lm (B). Data were analyzed by Mann–Whitney U test. *P < 0.05 versus scramble. LV, left ventricular; TUNEL,
transferase-mediated dUTP nick end labeling; MI, myocardial infarction; DDR2, discoidin domain receptor 2; Let-7c, lethal-7c.
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downregulated by the inhibitor. Thus, effects of Let-7c
antagomir used in this study may result from inhibition
of other members of the Let-7 family alongside with the
inhibition of Let-7c.
A hallmark feature of ventricular remodeling is deposi-
tion of excessive extracellular matrix and fibrosis (Doba-
czewski et al. 2010; Burchfield et al. 2013). In cardiac
pathologies, fibroblasts proliferate and secrete various
growth factors, collagen, and fibronectin (Camelliti et al.
2005; Krenning et al. 2010; Zeisberg and Kalluri 2010). Fi-
broblasts can be divided into subpopulations based on the
morphology and expression of cell surface markers, such
as DDR2 and FAP (Zeisberg and Kalluri 2010). DDR2+ fi-
broblasts are involved in cell migration and differentiation
(Camelliti et al. 2005; Krenning et al. 2010). To date, no
therapeutic strategy has been developed to specifically tar-
get fibrosis and fibroblast subpopulations in the heart. In
this study, parallel with the maintained systolic function,
we detected significantly decreased fibrosis, measured by
the amount of interstitial collagen deposits, in mice treated
with Let-7c inhibitor postinfarction. This was associated
with a lower number of DDR2+ fibroblasts and a tendency
for a smaller infarction scar size after MI. Hence, the
decreased fibrotic response may contribute to the
improved cardiac function in mice postinfarction by the
Let-7 miRNA inhibition. Interestingly, it has been reported
recently that in cultured human proximal tubular epithe-
lial cells, lipoxin-mediated upregulation of Let-7c sup-
presses transforming growth factor b1 (TGFb1)–induced
fibrosis (Brennan et al. 2013) and that in pancreatic cancer
cells both collagen and TGFb1 can attenuate Let-7c expres-
sion (Dagni-Garimella et al. 2011). However, in this study,
the expression of TGFb1 in heart was not affected by inhi-
bition of Let-7c. Taken together, these studies suggest dis-
tinct cell- and tissue-specific interplay and regulatory
circuits between profibrotic factors and Let-7c miRNA.
As the major finding of this study, we observed
decreased number of apoptotic cells in myocardium after
Let-7c inhibition, likely playing an important role in pre-
serving systolic function postinfarction. Let-7 family of
miRNAs is known to be involved in the regulation of cell
apoptosis (Roush and Slack 2008; Peter 2009). In cardio-
vascular system, for example, Let-7c overexpression
enhances apoptosis in endothelial cells, whereas inhibition
of Let-7c partly alleviates apoptotic cell death mediated
by oxidized-LDL (Qin et al. 2012). In that study, apopto-
sis was related to inhibition of Bcl-xL, an antiapoptotic
member of the Bcl-2 family, and a direct target of Let-7c
in endothelial cells. Apoptosis has also been linked to the
ability of Let-7 to target caspase-3, Bcl-2, cyclin-depen-
dent kinase 5, and Fas proteins (Barh et al. 2010). Inter-
estingly, the expression of Let-7a and Let-7b decreases
significantly following exposure to agents that induce
cellular stress, such as ionizing radiation (Saleh et al.
2011). Therefore, it is tempting to speculate that the
decrease in Let-7c miRNA levels observed in this study is
caused by MI-induced LV wall cell stress. Importantly,
because inhibition of Let-7c improved cardiac function,
our results suggest that the downregulation of Let-7c after
MI is beneficial, yet a short-term compensatory mecha-
nism. Interestingly, the expression of Let-7c miRNA has
also been shown to be downregulated in patients with
atrial fibrillation (Cooley et al. 2012), and thus Let-7c
miRNA may serve as a potential drug target in the pre-
vention and treatment of atrial fibrillation (Santulli et al.
2014). Recently, the functional role of the reverse atrial
remodeling in preventing atrial fibrillation has been dem-
onstrated also in the clinical setting (D’Ascia et al. 2011),
and thus, further studies are warranted to dissect the pos-
sible effect of Let-7 inhibition on atrial remodeling.
One of the key functions of Let-7 is to promote differ-
entiation of cells (Roush and Slack 2008; Peter 2009;
Heinrich and Dimmeler 2012). In C. elegans, this role was
shown by the requirement of Let-7 in halting the stem-
cell-like divisions of the seam cells and their consequent
adoption of a fully differentiated state (Reinhart et al.
2000). In more complex organisms, Let-7 expression dra-
matically increases as cells become more differentiated
(Roush and Slack 2008; Peter 2009). Recently, the stem-
cell factor Lin28 has been shown to be a major contribu-
tor to the posttranscriptional regulation of mammalian
Let-7 (Thornton and Gregory 2012; Shyh-Chang and
Daley 2013). Lin28 is highly expressed in undifferentiated
ES cells and represents part of a pluripotency network in
these cells with key ES cell transcription factors, such as
Oct4, Sox2, and Nanog (Marson et al. 2008). Reprogram-
ming of differentiated cells to iPS cells can be achieved by
the introduction of pluripotency transcription factors into
somatic cells (Yamanaka and Blau 2010). One of the first
studies reporting the derivation of human iPS cells uti-
lized ectopic expression of Oct4, Sox2, Nanog, and Lin28
as reprogramming factors (Yu et al. 2007). This observa-
tion, together with the report that Let-7 inhibition
enhances reprogramming of mouse fibroblasts to iPS cells
(Melton et al. 2010), shows that Lin28/Let-7 axis manipu-
lates cellular pluripotency. In line with these studies, we
provide evidence that the inhibition of Let-7 miRNA
increases expression of pluripotency genes Sox2 and Oct4
in cardiac fibroblasts in vitro and in normal mice heart in
vivo, and that modulation of Let-7 miRNAs can be used
to alter the phenotype of cardiac fibroblasts and concomi-
tantly affect cardiac function.
The fact that any given miRNA has the potential to tar-
get multiple mRNAs as well as a given mRNA is likely to
be targeted by several miRNAs (Dorn 2012) makes the
interpretation of the experimental results challenging. As
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described above, in this study the inhibition of Let-7
miRNA increased expression of pluripotency genes Sox2
and Oct4 in cardiac fibroblasts in vitro and in normal
mice heart in vivo. However, postinfarction alterations in
gene expression were not significant. The reasons for dis-
tinct changes remain to be established, but may be due to
the masking effect of myocardial tissue damage and asso-
ciated stress response (Dorn 2012). The ability of miRNAs
to impact on multiple effectors within a biological path-
way, on the other hand, facilitates their putative use as
therapeutic targets (van Rooij and Olson 2012; Seeger
et al. 2013). In this study, the inhibition of one family
member of Let-7 miRNAs led to altered expression of
several target genes in normal mice, and likely several
others – known or unknown – we did not evaluate in this
study. Moreover, because of a very high degree of homol-
ogy between members of Let-7 family, Let-7c antagomir
used in this study resulted in inhibition of other members
of the Let-7 family alongside with the inhibition of Let-
7c. Thus, the results obtained with one antagomir should
be interpreted with caution. Nevertheless, the fact that we
observed altered recovery of myocardium after ischemic
insult confirms that the modulation of miRNAs can be a
powerful tool.
Despite optimal treatment with existing therapeutics,
the rates of morbidity and mortality are still high in
patients with heart failure (Jessup and Brozena 2003;
McMurray and Pfeffer 2005), and novel therapeutic strat-
egies are necessary. In this study, we observed decreased
fibrosis and apoptosis, and subsequently maintained sys-
tolic function postinfarction in response to Let-7c inhibi-
tor. Thus, inhibition of Let-7 miRNA’s function may be a
novel therapeutic approach for detrimental postinfarction
LV remodeling. One concern of this approach, arising
from the understanding of Let-7 regulation, is the dual
role of Let-7 in being both protective and causal in differ-
ent types of disease. Like reported here with MI model,
Let-7 inhibition has also protective effect in mice with
diet-induced obesity (Frost and Olson 2011). However,
Let-7 is a tumor suppressor raising the likelihood that
persistent Let-7 repression may lead to hyperplastic disor-
ders and, in certain cases, cancer (Barh et al. 2010; Boye-
rinas et al. 2010). Thus, long-term experiments are
required to establish the safety of Let-7 inhibition.
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